Introduction
A startup closes its Series A with 6 patents and strong ARR. Eighteen months later, the Series B term sheet arrives — and so does the investor’s IP due diligence report. Three of the 6 patents have weak claim scope. One has a prior art problem that wasn’t identified during prosecution. The round is restructured at a lower valuation.
This scenario is not rare. IP now constitutes over 87% of enterprise value for S&P 500 technology companies. Institutional investors at the Series B stage know this — and their diligence frameworks have caught up. A patent portfolio that looked strong to the founding team may look very different through the lens of an investor’s IP analyst.
This article is the founder’s guide to what investors are actually checking in a patent portfolio at Series B, what mistakes show up most frequently in diligence, and how to run a pre-round audit before investors do it for you.
Why Patent Due Diligence Has Become a Series B Gating Issue
Early-stage investment rounds — pre-seed, seed, and Series A — often move too quickly for deep IP review. Investors at those stages are betting on the team and the market. By Series B, the story changes. Institutional investors, particularly those with in-house IP teams or relationships with specialist IP counsel, now run structured patent diligence as a standard part of the process.
The shift is data-driven: intangible assets now represent the majority of enterprise value for technology companies, and IP due diligence failures have been directly linked to down rounds, restructured terms, and deal collapses. A startup that arrives at Series B without a clean, mapped patent portfolio signals one of two things to an investor: the team hasn’t thought carefully about their IP, or they have and didn’t like what they found. Neither is a good signal.
The 5 Things Investors Actually Check in a Patent Portfolio
Investor IP diligence is not a single review — it is a structured assessment across five dimensions. Understanding each one helps founders see their portfolio the way an investor’s analyst sees it.
- Claim breadth- Are the claims narrow workarounds of prior art that were squeezed during prosecution, or do they give real exclusivity in the market? A patent with dependent claims doing all the commercial work is a weak patent. Investors want independent claims that would require a competitor to fundamentally change their product to design around.
- Portfolio-to-product mapping- Do the patents cover the product the company is actually selling-today-or do they reflect R&D from 3 years ago? A portfolio full of patents on features the product no longer uses is a maintenance cost, not an asset.
- Prosecution history- Is there file wrapper estoppel that limits how broadly the claims can be enforced? Arguments made to the examiner to distinguish prior art during prosecution can be used against the patentee in litigation. Investors check this.
- Validity risk- Has prior art been identified that could undermine key patents under § 102 (anticipation) or § 103 (obviousness)? A patent that is vulnerable to invalidity challenge is a much weaker asset than one that has been validity-screened.
- Ownership and assignment chain- Are all patents properly assigned from inventors to the company? This is especially relevant for startups with university research origins or founding team members who created IP before formal employment agreements were in place.
“Investors aren’t just asking whether you have patents. They’re asking whether those patents would actually stop a well-funded competitor. That’s a harder question — and most founders don’t know the answer before diligence starts.”
The Startup Patent Mistakes That Show Up in Diligence
These are the issues that appear most frequently in Series B IP diligence — and that are addressable if caught before the investor’s team finds them first:
- Continuation filings not paced with the product roadmap — the product has evolved but the pending continuation still covers the version from filing date
- Claims drafted to get granted, not to be enforced — narrow claims that sail through examination but offer minimal commercial protection
- Key technology left unprotected — the team assumed trade secret protection was sufficient and never filed on the core technical differentiator
- Inventor assignment gaps — IP created during pre-incorporation research or by contractors without proper assignment agreements
- No FTO opinion on the core product feature set — the company doesn’t know whether its flagship product infringes a competitor’s active patents
How to Run a Pre-Round Patent Portfolio Audit
A pre-round patent portfolio audit is the same analysis an investor’s team will run — done by the startup first, so there are no surprises. Here is the practical process:
- Map every patent to a specific product feature or revenue line.
If a patent doesn’t map to something the company is actively selling or expects to sell within 12 months, document why it’s still worth maintaining. If you can’t explain it, consider abandonment. - Run avalidity pre-screen on your 3 most important patents.
Commission a prior art search scoped to the independent claims of each patent. Would a strong reference survive a challenge under § 102 or § 103? Know before your investor does. - Check claim scope against your actual product.
Are the independent claims broad enough that a competitor couldn’t design around them with a minor modification? If not, is there a pending continuation that can be shaped to cover the commercial product more broadly? - Audit inventor assignments.
Confirm every inventor on every patent has a signed assignment agreement transferring rights to the company. Pay particular attention to patents with inventors who left the company, were contractors, or conducted research at a university. - Commission a gap analysis.
What technology is the company relying on — for current products and the next 18 months of roadmap — that isn’t yet protected? Unfiled technology is unprotected technology.
How TT Consultants Supports Pre-Round IP Readiness
TT Consultants patent portfolio analysis service is structured specifically for pre-round IP readiness — giving founders and their counsel the same view institutional investors will run, before the term sheet lands.
The service covers claim mapping against current product feature sets, validity pre-screening for key patents, prosecution history review, inventor assignment gap identification, and commercialization gap analysis. For startups heading into a funding round, TTC works alongside existing patent counsel — not as a replacement for legal advice, but as the analytical layer that turns a portfolio of patents into a coherent, investor-ready IP narrative.
Investor diligence is coming. Make sure your patent portfolio is ready. TT Consultants portfolio analysis service gives you the same view investors will get — before they do. → Contact Us
Conclusion: The Takeaway
A patent portfolio audit before a funding round isn’t a defensive exercise — it’s a strategic one. Investors at Series B are running structured IP diligence whether founders prepare for it or not. The question is whether the startup controls the narrative or reacts to the findings.
The founders who arrive at Series B with a clean, mapped, commercially relevant patent portfolio — with claim scope that actually protects their product and assignments that are airtight — close faster and at better terms. The ones who discover validity risk and assignment gaps during investor diligence are negotiating from behind.
The audit takes weeks. A repriced term sheet is permanent.
